In Brief: Antiflatulant labeling
This article was originally published in The Tan Sheet
Executive Summary
Antiflatulant labeling: FDA issues March 5 final rule amending the antiflatulant drug products monograph by adding the following possible statements of identity: "antiflatulant," "antigas," or "antiflatulant (antigas)." The rule also revises the allowable indications to include "alleviates [or relieves] the symptoms referred to as gas" or "alleviates [or relieves] bloating, pressure, fullness, or stuffed feeling, commonly referred to as gas." In addition, the rule states: "Antigas...may be used interchangeably with the term antiflatulant. Neither term should be considered as describing the mechanism of action of the active ingredient contained in the product." Comments on the amendment to the final rule must be received by FDA no later than June 3...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning